- Definitive business combination agreement signed between TriGemX Bio and TCGX Acquisition Corp.
- Combined company to be named TriGemX Bio, Inc., trading on Nasdaq under TGEM.
- Expected gross proceeds ~$246 million, including ~$86 million from TCGX trust (assuming no redemptions).
- Proceeds to fund Phase 3 trials for acute migraine (elismetrep), a prevention trial, and commercial readiness.
- Post-transaction equity value ~$600 million at closing (assuming no redemptions).
- TriGemX Bio shareholders roll 100% equity; no cash proceeds.
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card